VRAX
Virax Biolabs Group Limited Ordinary Shares
NASDAQ: VRAX · HEALTHCARE · BIOTECHNOLOGY
$2.93
+1.38% today
Updated 2026-07-29
Market cap
$3.02M
P/E ratio
—
P/S ratio
243.14x
EPS (TTM)
$-12.64
Dividend yield
—
52W range
$3 – $29
Volume
23.4M
Virax Biolabs Group Limited Ordinary Shares (VRAX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$2.93
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$1.65
Financial forecast
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.